{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T00:59:02Z","timestamp":1791593942313,"version":"4.3.4"},"reference-count":36,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Heart Failure"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.jchf.2023.03.025","type":"journal-article","created":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T14:51:14Z","timestamp":1684939874000},"page":"825-835","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Effect of Canagliflozin on Heart\u00a0Failure Hospitalization in Diabetes According to\u00a0Baseline Heart\u00a0Failure Risk"],"prefix":"10.1016","volume":"11","author":[{"given":"Muhammad Shahzeb","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew W.","family":"Segar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Shariq","family":"Usman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kershaw V.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8370-4569","authenticated-orcid":false,"given":"Harriette G.C.","family":"Van Spall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam D.","family":"DeVore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muthiah","family":"Vaduganathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn S.P.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7456-1570","authenticated-orcid":false,"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subodh","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javed","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.H. Wilson","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ambarish","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchf.2023.03.025_bib1","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2991\/jegh.k.191028.001","article-title":"Epidemiology of type 2 diabetes - global burden of disease and forecasted trends","volume":"10","author":"Khan","year":"2020","journal-title":"J\u00a0Epidemiol Glob Health"},{"key":"10.1016\/j.jchf.2023.03.025_bib2","doi-asserted-by":"crossref","first-page":"e722","DOI":"10.1161\/CIR.0000000000001040","article-title":"Comprehensive management of cardiovascular risk factors for adults with type 2 diabetes: a scientific statement from the American Heart Association","volume":"145","author":"Joseph","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2023.03.025_bib3","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.22190","article-title":"Temporal trends in heart failure incidence among Medicare beneficiaries across risk factor strata, 2011 to 2016","volume":"3","author":"Khera","year":"2020","journal-title":"Jama Netw Open"},{"key":"10.1016\/j.jchf.2023.03.025_bib4","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1001\/jamacardio.2020.5921","article-title":"Trends in hospitalizations for heart failure and ischemic heart disease among US adults with diabetes","volume":"6","author":"Honigberg","year":"2021","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jchf.2023.03.025_bib5","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1056\/NEJMoa1800256","article-title":"Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes","volume":"379","author":"Rawshani","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2023.03.025_bib6","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1161\/CIRCULATIONAHA.120.046783","article-title":"Risk factor control and cardiovascular event risk in people with type 2 diabetes in primary and secondary prevention settings","volume":"142","author":"Wright","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2023.03.025_bib7","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1001\/jamacardio.2020.4511","article-title":"Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis","volume":"6","author":"McGuire","year":"2021","journal-title":"Jama Cardiol"},{"key":"10.1016\/j.jchf.2023.03.025_bib8","doi-asserted-by":"crossref","first-page":"372","DOI":"10.2337\/dc21-1815","article-title":"Utilization rates of SGLT2 inhibitors and GLP-1 receptor agonists and their facility-level variation among patients with atherosclerotic cardiovascular disease and type 2 diabetes: insights from the Department of Veterans Affairs","volume":"45","author":"Mahtta","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jchf.2023.03.025_bib9","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1016\/j.jacc.2018.08.2202","article-title":"Prescriber patterns of SGLT2i after expansions of U.S. Food and Drug Administration labeling","volume":"72","author":"Vaduganathan","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2023.03.025_bib10","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.2337\/dc19-0587","article-title":"Machine learning to predict the risk of incident heart failure hospitalization among patients with diabetes: the WATCH-DM Risk Score","volume":"42","author":"Segar","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jchf.2023.03.025_bib11","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1161\/CIRCULATIONAHA.119.042685","article-title":"Heart failure risk stratification and efficacy of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes mellitus","volume":"140","author":"Berg","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2023.03.025_bib12","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2023.03.025_bib13","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ahj.2013.05.007","article-title":"Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)\u2014a randomized placebo-controlled trial","volume":"166","author":"Neal","year":"2013","journal-title":"Am Heart J"},{"key":"10.1016\/j.jchf.2023.03.025_bib14","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/dom.12829","article-title":"Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): A randomized, placebo-controlled trial","volume":"19","author":"Neal","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jchf.2023.03.025_bib15","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1161\/CIRCULATIONAHA.118.034222","article-title":"Canagliflozin and heart failure in type 2 diabetes mellitus: results from the CANVAS Program","volume":"138","author":"Radholm","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2023.03.025_bib16","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/j.jacc.2021.08.009","article-title":"Comparative reductions in investigator-reported and adjudicated ischemic events in REDUCE-IT","volume":"78","author":"Gaba","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2023.03.025_bib17","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1016\/S0140-6736(18)31184-X","article-title":"Endpoints in diabetes cardiovascular outcome trials","volume":"391","author":"Patel","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jchf.2023.03.025_bib18","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.119.006720","article-title":"Comparison of outcome adjudication by investigators and by a central end point committee in heart failure trials: experience of the SHIFT Heart\u00a0Failure Study","volume":"13","author":"Tyl","year":"2020","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jchf.2023.03.025_bib19","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/ejhf.2375","article-title":"Incorporation of natriuretic peptides with clinical risk scores to predict heart failure among individuals with dysglycaemia","volume":"24","author":"Segar","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2023.03.025_bib20","article-title":"Validation of the WATCH-DM and TRS-HFDM risk scores to predict the risk of incident hospitalization for heart failure among adults with type 2 diabetes: a multicohort analysis","volume":"11","author":"Segar","year":"2022","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jchf.2023.03.025_bib21","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1111\/dom.14283","article-title":"Prediction of heart failure outcomes in patients with type 2 diabetes mellitus: validation of the Thrombolysis in Myocardial Infarction Risk Score for Heart\u00a0Failure in Diabetes (TRS-HFDM) in patients in the ACCORD trial","volume":"23","author":"Elharram","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jchf.2023.03.025_bib22","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1001\/jama.1982.03320430047030","article-title":"Evaluating the yield of medical tests","volume":"247","author":"Harrell","year":"1982","journal-title":"JAMA"},{"key":"10.1016\/j.jchf.2023.03.025_bib23","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1161\/CIRCULATIONAHA.109.849166","article-title":"Cardiovascular risk prediction: basic concepts, current status, and future directions","volume":"121","author":"Lloyd-Jones","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2023.03.025_bib24","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1136\/bmj.319.7223.1492","article-title":"Calculating the number needed to treat for trials where the outcome is time to an event","volume":"319","author":"Altman","year":"1999","journal-title":"BMJ"},{"key":"10.1016\/j.jchf.2023.03.025_bib25","series-title":"Modeling Survival Data: Extending the Cox Model","author":"Therneau","year":"2000"},{"key":"10.1016\/j.jchf.2023.03.025_bib26","author":"Harrell"},{"issue":"3","key":"10.1016\/j.jchf.2023.03.025_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v065.i03","article-title":"simPH: An R Package for illustrating estimates from Cox proportional hazard models including for interactive and nonlinear effects","volume":"65","author":"Gandrud","year":"2015","journal-title":"Journal of Statistical Software"},{"key":"10.1016\/j.jchf.2023.03.025_bib28","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2023.03.025_bib29","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1111\/dom.14015","article-title":"Empagliflozin reduces the risk of mortality and hospitalization for heart failure across Thrombolysis In Myocardial Infarction Risk Score for Heart\u00a0Failure in Diabetes categories: Post hoc analysis of the EMPA-REG OUTCOME trial","volume":"22","author":"Verma","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jchf.2023.03.025_bib30","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1089\/dia.2019.0213","article-title":"Adoption of new glucose-lowering medications in the U.S.-the case of SGLT2 inhibitors: nationwide cohort study","volume":"21","author":"McCoy","year":"2019","journal-title":"Diabetes Technol Ther"},{"issue":"10","key":"10.1016\/j.jchf.2023.03.025_bib31","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1016\/j.jacc.2019.03.010","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"74","author":"Arnett","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2023.03.025_bib32","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1161\/CIRCULATIONAHA.119.043337","article-title":"Incorporation of biomarkers into risk assessment for allocation of antihypertensive medication according to the 2017 ACC\/AHA High Blood Pressure Guideline: a pooled cohort analysis","volume":"140","author":"Pandey","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2023.03.025_bib33","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.2337\/dc21-1170","article-title":"A\u00a0biomarker-based score for risk of hospitalization for heart failure in patients with diabetes","volume":"44","author":"Berg","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jchf.2023.03.025_bib34","first-page":"215","article-title":"Biomarker-based risk prediction of incident heart failure in pre-diabetes and diabetes","volume":"9","author":"Pandey","year":"2021","journal-title":"J\u00a0Am Coll Cardiol HF"},{"key":"10.1016\/j.jchf.2023.03.025_bib35","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1161\/CIRCULATIONAHA.119.044865","article-title":"Association of intensive lifestyle intervention, fitness, and body mass index with risk of heart failure in overweight or obese adults with type 2 diabetes mellitus: an analysis from the Look AHEAD Trial","volume":"141","author":"Pandey","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2023.03.025_bib36","first-page":"999","article-title":"Adiposity and incident heart failure and its subtypes: MESA (Multi-Ethnic Study of Atherosclerosis)","volume":"6","author":"Rao","year":"2018","journal-title":"J\u00a0Am Coll Cardiol HF"}],"container-title":["JACC: Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177923001865?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177923001865?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:03:22Z","timestamp":1761973402000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213177923001865"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":36,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S2213177923001865"],"URL":"https:\/\/doi.org\/10.1016\/j.jchf.2023.03.025","relation":{},"ISSN":["2213-1779"],"issn-type":[{"value":"2213-1779","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of Canagliflozin on Heart\u00a0Failure Hospitalization in Diabetes According to\u00a0Baseline Heart\u00a0Failure Risk","name":"articletitle","label":"Article Title"},{"value":"JACC: Heart Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchf.2023.03.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}